Eidos Therapeutics, Inc. (EIDX)
|Net Income (ttm)||-100.83M|
|Trading Day||January 25|
|Day's Range||116.77 - 128.49|
|52-Week Range||38.03 - 131.58|
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigation of Eidos Therapeutics, Inc. Buyout
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ GS: EIDX) regarding possible breaches of fid...
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - EIDX, RESI, PE, ARA
NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violati...
SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provide...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Eidos Therapeutics, Inc. -EIDX
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
EIDOS THERAPEUTICS INVESTOR ALERT BY The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eidos Therapeutics, Inc. - EIDX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Eidos Th...
EIDX INVESTIGATION – Shareholder Rights Firm Labaton Sucharow is Investigating Eidos Therapeutics (NASDAQ: EIDX) for Potential Securities Violations and Breach of Fiduciary Duty
NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-...
NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Eidos Therapeutics, Inc. ("EID...
Eidos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Eidos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – EIDX
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Eidos Therapeutics, Inc. (NASDAQ: EIDX) to BridgeBio Pharma, Inc. is fair t...
BridgeBio announced plans to fully acquire the biotech.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of BridgeBio Pharma, Inc. with Eidos Therapeutics, Inc. is Fair to BBIO Shareholders
New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...
BridgeBio Pharma Inc (NASDAQ: BBIO) said on Monday that it will increase its stake in Eidos Therapeutics Inc (NASDAQ: EIDX) by 36.3% in a cash deal that is valued at £134.95 million (aggregate...
(EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal?
SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Eidos Therapeutics, Inc. ("Eidos" or the...
BridgeBio Pharma Inc. BBIO, announced Monday an agreement to buy Eidos Therapeutics Inc. EIDX, -0.30% in a deal that values Eidos at about $2.83 billion. Eidos's stock is currently halted for ...
BridgeBio to Acquire All Outstanding Shares of E idos it Does Not Already Own
Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors
SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...
SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the second quarter ended June 30, 2020 and provided...
Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided ...
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.
Eidos Therapeutics (EIDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Helping people stricken with illness can be richly rewarding in more ways than one.
Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.
It’s David vs. Goliath.
Eidos Therapeutics, Inc. (EIDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation
The sales figure for Vyndaqel shows the market potential for several smaller players' pipeline candidates.
BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet...
SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference...
Can their share prices continue to climb?
This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower pr...
Eidos Therapeutics, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
|IPO Date |
Jun 20, 2018
|Stock Exchange |
|Ticker Symbol |
According to 7 analysts, the average rating for EIDX stock is "Hold." The 12-month stock price forecast is 78.71, which is a decrease of -35.59% from the latest price.